2016. ESMO – Evaluating a Novel Oncologist-led BRCA1/2 Mutation (BRCAm) Testing and Counseling Model for Patients with Ovarian cancer: Interim Results from the ENGAGE (NCT02406235) study

Scambia G, Chalas E, Huang G, Graña Suárez B, Santiago SG, Colombo N, Pignata S, Huot-Marchand P, Karve S, Blakeley C. Evaluating a Novel Oncologist-led BRCA1/2 Mutation (BRCAm) Testing and Counseling Model for Patients with Ovarian cancer: Interim results from the ENGAGE (NCT02406235) study. Annals of Oncology, 2016 October;27(suppl_6):LBA34. Presented at: ESMO 2016 Annual Congress; October 6-11, 2016; Copenhagen, Denmark.